Maria Orietta Borghi

List of Publications by Citations

 $\textbf{Source:} \ https://exaly.com/author-pdf/1901138/maria-orietta-borghi-publications-by-citations.pdf$

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61 38 4,250 122 h-index g-index citations papers 5,004 134 5.13 5.9 avg, IF L-index ext. papers ext. citations

#	Paper	IF	Citations
122	Pathogenesis of antiphospholipid syndrome: understanding the antibodies. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 330-9	8.1	374
121	Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. <i>Blood</i> , 2003 , 101, 3495-500	2.2	260
120	Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 236-50	5.3	173
119	Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1327-33	2.4	160
118	TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. <i>Aids</i> , 1994 , 8, 757-62	3.5	134
117	Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1602-13		118
116	A non-complement-fixing antibody to 2 glycoprotein I as a novel therapy for antiphospholipid syndrome. <i>Blood</i> , 2014 , 123, 3478-87	2.2	98
115	Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 609-15	2.4	97
114	Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. <i>Acta Neuropathologica Communications</i> , 2016 , 4, 47	7-3	96
113	In vivo distribution of 🛭 glycoprotein I under various pathophysiologic conditions. <i>Blood</i> , 2011 , 118, 4231-8	2.2	89
112	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2020 , 11, 584241	8.4	86
111	Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1155-64	9.5	76
110	Endothelial cell activation by antiphospholipid antibodies. <i>Clinical Immunology</i> , 2004 , 112, 169-74	9	76
109	Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease. <i>Journal of Bone and Mineral Research</i> , 2004 , 19, 1112-21	6.3	75
108	Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against 2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2196-204	9.5	68
107	Inflammatory response and the endothelium. <i>Thrombosis Research</i> , 2004 , 114, 329-34	8.2	62
106	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 433-440	8.1	61

105	Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 35-43	8.1	59
104	Patients with antiphospholipid syndrome display endothelial perturbation. <i>Journal of Autoimmunity</i> , 2010 , 34, 105-10	15.5	59
103	Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. <i>Clinical Immunology and Immunopathology</i> , 1992 , 63, 267-74		59
102	In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. <i>Lupus</i> , 1996 , 5, 139-45	2.6	57
101	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. Journal of Autoimmunity, 2021 , 116, 102560	15.5	57
100	Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 608-11	2.4	54
99	Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2468-71		52
98	Heterogeneity of immune responsiveness in healthy elderly subjects. <i>Clinical Immunology and Immunopathology</i> , 1988 , 47, 142-51		52
97	Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. <i>Lupus</i> , 2008 , 17, 937-42	2.6	51
96	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. <i>Blood</i> , 2016 , 127, 365-7	2.2	51
95	Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the 2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. <i>Journal of Autoimmunity</i> , 2012 , 38, J209-15	15.5	47
94	Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2004 , 3, 510-5	13.6	47
93	Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. <i>British Journal of Haematology</i> , 2004 , 126, 85-92	4.5	46
92	Humoral autoimmunity against endothelium: theory or reality?. <i>Trends in Immunology</i> , 2005 , 26, 275-81	14.4	45
91	Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. <i>Immunologic Research</i> , 2013 , 56, 432-8	4.3	43
90	Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1504-12		43
89	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018 , 17, 1153-1168	13.6	43
88	2 -glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. <i>Journal of Autoimmunity</i> , 2014 , 55, 42-50	15.5	42

87	In vivo immunopotentiating activity of thymopentin in aging humans: increase of IL-2 production. <i>Clinical Immunology and Immunopathology</i> , 1987 , 42, 151-9		42
86	Beyond thrombosis: Anti- 2 GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018 , 90, 76-83	15.5	41
85	Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. <i>International Immunology</i> , 2001 , 13, 349-57	4.9	39
84	Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. <i>Journal of Cellular and Molecular Medicine</i> , 2012 , 16, 1563-72	5.6	37
83	Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. <i>Lupus</i> , 2010 , 19, 453-6	2.6	37
82	Obstetric and vascular APS: same autoantibodies but different diseases?. <i>Lupus</i> , 2012 , 21, 708-10	2.6	34
81	Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2012 , 14, R271	5.7	32
80	Update on the pathogenesis and treatment of the antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 476-82	5.3	29
79	Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. <i>Lupus</i> , 2007 , 16, 651-6	2.6	29
78	I Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome. <i>Journal of Immunology</i> , 2017 , 198, 2640-2648	5.3	28
77	Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 715-726	8.1	28
76	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2018 , 9, 1388	8.4	28
75	Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss. <i>Clinical Reviews in Allergy and Immunology</i> , 2008 , 34, 332-7	12.3	27
74	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1073-1085	9.5	27
73	In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from high-risk HIV-negative intravenous drug users. <i>Aids</i> , 1995 , 9, 691-4	3.5	26
72	Immune parameters identify Italian centenarians with a longer five-year survival independent of their health and functional status. <i>Experimental Gerontology</i> , 2014 , 54, 14-20	4.5	25
71	Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. <i>Arthritis Research and Therapy</i> , 2016 , 18, 111	5.7	24
70	The challenges of lupus anticoagulants. <i>Expert Review of Hematology</i> , 2016 , 9, 389-400	2.8	24

69	Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA. <i>PLoS ONE</i> , 2014 , 9, e107743	3.7	24
68	8-Chloro-cyclic AMP and protein kinase A I-selective cyclic AMP analogs inhibit cancer cell growth through different mechanisms. <i>PLoS ONE</i> , 2011 , 6, e20785	3.7	23
67	Transforming growth factor beta1 in the pathogenesis of autoimmune congenital complete heart block: lesson from twins and triplets discordant for the disease. <i>Arthritis and Rheumatism</i> , 2006 , 54, 35	6-9	23
66	In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse. <i>Immunopharmacology</i> , 1992 , 24, 11-6		23
65	Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: Report of a family with multiple anti-phospholipid positive members. <i>Journal of Autoimmunity</i> , 2009 , 32, 60-3	15.5	21
64	New insight into antiphospholipid syndrome: antibodies to 🛭 glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , 2019 , 104, 819-826	6.6	21
63	Interaction between chronically HIV-infected promonocytic cells and human umbilical vein endothelial cells: role of proinflammatory cytokines and chemokines in viral expression modulation. <i>Clinical and Experimental Immunology</i> , 2000 , 120, 93-100	6.2	20
62	Anti-beta-2 glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1069, 364-76	6.5	19
61	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. <i>Rheumatology</i> , 2021 , 60, 1114-1124	3.9	19
60	Synergistic activity of everolimus and 5-aza-2Fdeoxycytidine in medullary thyroid carcinoma cell lines. <i>Molecular Oncology</i> , 2017 , 11, 1007-1022	7.9	18
59	Role of anti-beta2 glycoprotein I antibodies in antiphospholipid syndrome: in vitro and in vivo studies. <i>Clinical Reviews in Allergy and Immunology</i> , 2007 , 32, 67-74	12.3	18
58	Diagnostic laboratory tests for systemic autoimmune rheumatic diseases: unmet needs towards harmonization. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 56, 1743-1748	5.9	17
57	Toll-like receptor 4 and 🛭 glycoprotein I interaction on endothelial cells. <i>Lupus</i> , 2014 , 23, 1302-4	2.6	17
56	Detection of early endothelial damage in patients with Raynaud's phenomenon. <i>Microvascular Research</i> , 2017 , 113, 22-28	3.7	16
55	Endothelium activation in the anti-phospholipid syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2003 , 57, 282-6	7.5	16
54	The effects of deoxyspergualin on the development of diabetes in diabetes-prone BB rats. <i>Scandinavian Journal of Immunology</i> , 1992 , 36, 415-20	3.4	16
53	Interleukin-17/Interleukin-21 and Interferon-[producing T cells specific for I Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome. <i>Haematologica</i> , 2019 , 104, 2519-2527	6.6	15
52	Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1388-92	2.4	15

51	In vivo immunopotentiating activity of thymopentin in aging humans: modulation of IL-2 receptor expression. <i>Clinical Immunology and Immunopathology</i> , 1988 , 48, 140-9		15
50	Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e50	2.4	15
49	Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. <i>Arthritis Research and Therapy</i> , 2018 , 20, 187	5.7	15
48	Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2019 , 10, 773	8.4	14
47	IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1201-2		14
46	Beta-endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects. <i>Peptides</i> , 1994 , 15, 769-75	3.8	14
45	The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines. <i>Endocrine</i> , 2016 , 51, 101-12	4	13
44	In utero exposure to Azathioprine in autoimmune disease. Where do we stand?. <i>Autoimmunity Reviews</i> , 2020 , 19, 102525	13.6	13
43	Autoantibody profiling in APS. <i>Lupus</i> , 2014 , 23, 1262-4	2.6	12
42	International standards for IgG and IgM anti-Iglycoprotein antibody measurement. <i>Lupus</i> , 2014 , 23, 1317-9	2.6	12
41	Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1764-17	6 99	11
40	Anti-🛘 glycoprotein I ELISA assay: The influence of different antigen preparations. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 789-791	7	11
39	FK-506 prevents diabetes in diabetes-prone BB/Wor rats. <i>International Journal of Immunopharmacology</i> , 1991 , 13, 1027-30		10
38	Protection from experimental autoimmune thyroiditis in CBA mice with the novel immunosuppressant deoxyspergualin. <i>Scandinavian Journal of Immunology</i> , 1994 , 39, 333-6	3.4	9
37	Antitumor activity of interferon-la in hormone refractory prostate cancer with neuroendocrine differentiation. <i>Journal of Endocrinological Investigation</i> , 2017 , 40, 761-770	5.2	8
36	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. <i>Autoimmunity Reviews</i> , 2020 , 19, 102509	13.6	8
35	Oxidation of <code>Q</code> -glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. <i>PLoS ONE</i> , 2017 , 12, e0186513	3.7	8
34	Interferon-inducible genes, TNF-related apoptosis-inducing ligand (TRAIL) and interferon inducible protein 27 (IFI27) are negatively regulated in leiomyomas: implications for a role of the interferon pathway in leiomyoma development. <i>Gynecological Endocrinology</i> 2012 , 28, 216-9	2.4	8

33	Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome 2020 ,		8	
32	Immunopharmacological activity of cefodizime in young and elderly subjects: in vitro and ex vivo studies. <i>Infection</i> , 1992 , 20 Suppl 1, S61-3	5.8	7	
31	Complement Activation and Thrombin Generation by MBL Bound to 2 -Glycoprotein I. <i>Journal of Immunology</i> , 2020 , 205, 1385-1392	5.3	7	
30	Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 265	5.7	5	
29	Prevalence of autoantibodies against structure specific recognition protein 1 in systemic lupus erythematosus. <i>Lupus</i> , 2004 , 13, 463-8	2.6	5	
28	Immunosuppressive activity of 15-deoxyspergualin on normal and autoimmune peripheral blood mononuclear cells. <i>European Journal of Pharmacology</i> , 1996 , 311, 213-20	5.3	5	
27	Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques. <i>Analytical Biochemistry</i> , 2019 , 566, 133-138	3.1	5	
26	Enrichment of IgG anti-DNA-producing lymphoblastoid cell lines by antigen-coated immunomagnetic beads. <i>Clinical Immunology and Immunopathology</i> , 1992 , 65, 39-44		4	
25	Experiences with immunomodulant agents in HIV infections. <i>Acta Haematologica</i> , 1987 , 78 Suppl 1, 84-	9 0 .7	4	
24	Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One. <i>Frontiers in Immunology</i> , 2021 , 12, 726820	8.4	4	
23	European Forum on Antiphospholipid Antibodies: research in progress. <i>Lupus</i> , 2009 , 18, 924-9	2.6	3	
22	Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009 , 10, 55-67	0.3	3	
21	Vitamin D and Anti-Phospholipid Antibody Syndrome: A Comprehensive Review. <i>Open Rheumatology Journal</i> , 2018 , 12, 248-260	0.2	3	
20	Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical Study. <i>Neuroendocrinology</i> , 2021 , 111, 937-950	5.6	3	
19	I glycoprotein I participates in phagocytosis of apoptotic neurons and in vascular injury in experimental brain stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 41, 2038-2053	7.3	3	
18	Effects of human recombinant type I IFNs (IFN-2D and IFN-1Da) on growth and migration of primary endometrial stromal cells from women with deeply infiltrating endometriosis: A preliminary study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 230, 192-	2.4 198	3	
17	ANTI-ENDOTHELIAL CELL AUTOANTIBODIES 2007 , 725-731		2	
16	Antiphospholipid and antiendothelial antibodies. <i>International Archives of Allergy and Immunology</i> , 1996 , 111, 320-5	3.7	2	

15	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests 2017 , 171-187		2
14	Histone Deacetylase Inhibitors Ameliorate Morphological Defects and Hypoexcitability of iPSC-Neurons from Rubinstein-Taybi Patients. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
13	Two Novel Technologies for the Detection of Anti-cardiolipin and Anti 🛭 -Glycoprotein Antibodies in the Real Life: Chemiluminescent in Comparison to the Addressable Laser Bead Immunoassays. <i>Immunological Investigations</i> , 2020 , 49, 58-68	2.9	2
12	Cerebrospinal fluid phosphorylated neurofilament heavy chain and chitotriosidase in primary lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 221-223	5.5	2
11	8-Cl-cAMP and PKA I-selective cAMP analogs effectively inhibit undifferentiated thyroid cancer cell growth. <i>Endocrine</i> , 2017 , 56, 388-398	4	1
10	In vitro and ex vivo effect of tiaprofenic acid on human peripheral blood mononuclear cells. <i>International Journal of Immunopharmacology</i> , 1992 , 14, 1279-84		1
9	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases		1
8	Antibodies and diagnostic tests in antiphosholipid syndrome 2021 , 565-574		1
7	Mechanisms of Action of the Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017 , 12, 31-46	0.3	0
6	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity? 2012 , 79-101		O
5	Antiendothelial Cell Antibodies 2014 , 723-729		
4	A5.5 Antibodies against Domain I of 🛭 Glycoprotein I in Antiphospholipid Antibody Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A31.3-A32	2.4	
3	What is the Genetics of Antiphospholipid Antibodies/Syndrome? 2012, 41-56		
2	Immunopotentiating Activity of Thymopentin Treatment in Elderly Subjects 1990 , 537-550		

Antibodies and Diagnostic Tests in Antiphospholipid Syndrome 2016, 495-501